~~<i id='04AA370C22'><strike id='04AA370C22'><tt id='04AA370C22'><pre id='04AA370C22'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：comprehensive 2025-10-02 15:36:02 Page View：29

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to fix cancer clinical trials' diversity problem
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

leisure time

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Future doctors need a strong humanities education

AdobeIfyouwantanargumentinfavorofteachingthehumanities,Isuggestyouaskamedicaleducator.AcrosstheU.S.,

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Flu vaccine reformulation won't be easy, manufacturers warn

AdobeLastfall,theWorldHealthOrganizationandsomenationaldrugregulatorsurgedinfluenzavaccinemanufactur